Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug ApprovalsNEW YORK,...
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults...
LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a...
Seamless scalability via the flexible reactor facilitates significant time savings throughout development stage up to market supplyLEON achieved superior accuracy...
ODENSE, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell...
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call...
CHATHAM, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing,...
Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2...
Mainz, Germany, December 28, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO...
OSLO, Norway, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the...
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate...
Total considerations of up to USD 83 million with the majority secured for Phase 2 development of the multivalent MVA-BN®...
Saint-Herblain (France), December 23, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that...
Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee...
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics , a clinical-stage drug discovery and development company focusing on novel...
MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable...